scholarly journals Measurement of Immunoglobulin G against Mycobacterial Antigen A60 in Patients with Cystic Fibrosis and Lung Infection Due to Mycobacterium abscessus

2005 ◽  
Vol 40 (1) ◽  
pp. 58-66 ◽  
Author(s):  
A. Ferroni ◽  
I. Sermet-Gaudelus ◽  
M. L. Bourgeois ◽  
C. Pierre-Audigier ◽  
C. Offredo ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Immunoglobulin G ◽  
Lung Infection ◽  
Mycobacterium Abscessus ◽  
Mycobacterial Antigen ◽  
Antigen A60

scholarly journals Pilot study to test inhaled nitric oxide in cystic fibrosis patients with refractory Mycobacterium abscessus lung infection

2020 ◽  
Vol 19 (2) ◽  
pp. 225-231 ◽  
Author(s):  
Lea Bentur ◽  
Michal Gur ◽  
Moshe Ashkenazi ◽  
Galit Livnat-Levanon ◽  
Marko Mizrahi ◽  
...  
Keyword(s):  
Nitric Oxide ◽  
Cystic Fibrosis ◽  
Pilot Study ◽  
Lung Infection ◽  
Mycobacterium Abscessus ◽  
Inhaled Nitric Oxide

scholarly journals Genetic diversification of persistent Mycobacterium abscessus within Cystic Fibrosis patients

2021 ◽  
Author(s):  
Astrid Lewin ◽  
Elisabeth Kamal ◽  
Torsten Semmler ◽  
Katja Winter ◽  
Sandra Kaiser ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Control Strategies ◽  
Cholesterol Oxidase ◽  
Treatment Strategies ◽  
Gene Mutations ◽  
Enrichment Analysis ◽  
Lung Infection ◽  
Mycobacterium Abscessus ◽  
Wide Range ◽  
Chronic Lung Infection

AbstractMycobacterium (M.) abscessus infections in Cystic Fibrosis (CF) patients cause a deterioration of lung function. Treatment of these multidrug-resistant pathogens is associated with severe side-effects, while frequently unsuccessful. Insight on M. abscessus genomic evolvement during chronic lung infection would be beneficial for improving treatment strategies. A longitudinal study enrolling 42 CF patients was performed at a CF center in Berlin, Germany, to elaborate phylogeny and genomic diversification of in-patient M. abscessus. Eleven of the 42 CF patients were infected with M. abscessus. Global human-transmissible M. abscessus cluster strains were isolated from five of these 11 patients. Phylogenetic analysis of 88 genomes from isolates of the 11 patients excluded occurrence of M. abscessus transmission among members of the study group. Genome sequencing and variant analysis of 30 isolates from 11 serial respiratory samples collected over four years from a chronically infected patient demonstrated accumulation of gene mutations. In total, 53 genes exhibiting non-synonymous variations were identified. Enrichment analysis emphasized genes involved in synthesis of glycopeptidolipids, genes from the embABC (arabinosyltransferase) operon, betA (glucose-methanol-choline oxidoreductase) and choD (cholesterol oxidase). Genetic diversity evolved in a variety of virulence- and resistance-associated genes. The strategy of M. abscessus populations in chronic lung infection is not clonal expansion of dominant variants, but to sustain simultaneously a wide range of genetic variants facilitating adaptation of the population to changing living conditions in the lung. Genomic diversification during chronic infection requires increased attention when new control strategies against M. abscessus infections are explored.

scholarly journals Anti-pseudomonad Activity of Manuka Honey and Antibiotics in a Specialized ex vivo Model Simulating Cystic Fibrosis Lung Infection

2019 ◽  
Vol 10 ◽  
Author(s):  
Aled E. L. Roberts ◽  
Lydia C. Powell ◽  
Manon F. Pritchard ◽  
David W. Thomas ◽  
Rowena E. Jenkins
Keyword(s):  
Cystic Fibrosis ◽  
Ex Vivo ◽  
Lung Infection ◽  
Cystic Fibrosis Lung ◽  
Manuka Honey ◽  
Ex Vivo Model

scholarly journals Decontamination Strategies Used for AFB Culture Significantly Reduce the Viability of Mycobacterium abscessus Complex in Sputum Samples from Patients with Cystic Fibrosis

2021 ◽  
Vol 9 (8) ◽  
pp. 1597
Author(s):  
Dominic Stephenson ◽  
Audrey Perry ◽  
Andrew Nelson ◽  
Ali E. Robb ◽  
Matthew F. Thomas ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Oxalic Acid ◽  
Nontuberculous Mycobacteria ◽  
Optimal Recovery ◽  
Mycobacterium Abscessus ◽  
Colony Count ◽  
Respiratory Pathogens ◽  
Quantitative Culture ◽  
Mycobacterium Abscessus Complex ◽  
Oxalic Acids

Nontuberculous mycobacteria are important respiratory pathogens in patients with cystic fibrosis (CF). For diagnosis, international guidelines recommend culture of sputum that has been decontaminated via chemical treatment. Fifty-six sputum samples from 32 patients known to be previously colonized or infected with NTM were subdivided, and the aliquots were subjected to six different decontamination strategies, followed by quantitative culture for NTM. Thirty sputum samples contained Mycobacterium abscessus complex (MABSC) and 11 contained Mycobacterium avium complex (MAC). Decontamination strategies included treatment with N-acetyl L-cysteine with 2% sodium hydroxide (NALC-NaOH), 4% NaOH, 1% chlorhexidine, 0.5 N sulfuric acid, 5% oxalic acid, double decontamination with NALC-NaOH, followed by 5% oxalic acid, and saline (0.85%) as a control. The samples were also cultured directly with no treatment. Treatment with NALC-NaOH resulted in an average reduction in colony count of 87% for MABSC when compared with direct culture. NaOH at 4% caused a 98.3% average reduction in colony count. All treatments that included NaOH resulted in colony counts that were statistically lower than those obtained from direct culture or the saline-treated control (p < 0.05). Standard treatments using sulfuric or oxalic acids were less deleterious, but still resulted in an average reduction in colony count of at least 30%. The viability of MAC was much less affected by most decontamination treatments. In conclusion, the viability of MABSC was severely compromised by standard decontamination regimens. This supports recent evidence showing that optimal recovery of MABSC is achieved by culture on an appropriate selective agar without decontamination of sputum samples.

scholarly journals Comparing Mycobacterium massiliense and Mycobacterium abscessus lung infections in cystic fibrosis patients

2015 ◽  
Vol 14 (1) ◽  
pp. 63-69 ◽  
Author(s):  
Anne-Laure Roux ◽  
Emilie Catherinot ◽  
Nathalie Soismier ◽  
Beate Heym ◽  
Gil Bellis ◽  
...  
Keyword(s):  
Cystic Fibrosis ◽  
Mycobacterium Abscessus ◽  
Mycobacterium Massiliense ◽  
Lung Infections

Apramycin overcomes the inherent lack of antimicrobial bactericidal activity in Mycobacterium abscessus

2021 ◽  
Author(s):  
Petra Selchow ◽  
Diane J. Ordway ◽  
Deepshikha Verma ◽  
Nicholas Whittel ◽  
Aline Petrig ◽  
...  
Keyword(s):  
Bactericidal Activity ◽  
Lung Infection ◽  
Resistance Mechanisms ◽  
Mycobacterium Abscessus ◽  
Multi Drug Resistance ◽  
Emerging Pathogen ◽  
Aminoglycoside Resistance ◽  
Treatment Regimens ◽  
Distinct Structure ◽  
Poor Therapeutic Outcome

Antibiotic therapy of infections caused by the emerging pathogen Mycobacterium abscessus is challenging due to the organism’s inherent resistance towards clinically available antimicrobials. The low bactericidal potency of currently available treatment regimens is of concern and testifies to the poor therapeutic outcome in pulmonary M. abscessus infections. Mechanistically, we here demonstrate that the acetyltransferase Eis2 is responsible for the lack of bactericidal activity of amikacin, the standard aminoglycoside used in combination treatment. In contrast, the distinct structure aminoglycoside apramycin is not modified by any of the pathogen’s innate aminoglycoside resistance mechanisms nor is it affected by the multi-drug resistance regulator WhiB7. As a consequence, apramycin uniquely shows potent bactericidal activity against M. abscessus . This favourable feature of apramycin is reflected in a mouse model of M. abscessus lung infection, which demonstrates superior activity over amikacin. These findings encourage the development of apramycin for the treatment of M. abscessus infections and suggest that M. abscessus eradication in lung pulmonary disease may be within therapeutic reach.

Sign in / Sign up

Export Citation Format

Share Document